Authors' response re: Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.
نویسندگان
چکیده
The stated hospitalization cost of $8530 (2009$) is not representative of respiratory syncytial virus (RSV) hospitalizations among palivizumab-eligible infants; it is the average cost of bronchiolitis hospitalizations among US children ,2 years.2 Using the same source, the Kids’ Inpatient Database, the average RSV hospitalization (International Classification of Diseases, Ninth Revision, Clinical Modification 079.6, 466.11, 480.1) cost for all infants was $14 832 (2009$). Among high-risk infants, costs of RSV hospitalization and associated care through 12 months of age range from $20 160 to $39 399 (2010$).3
منابع مشابه
Clarifying Costs and Benefits of Respiratory Syncytial Virus Immunoprophylaxis
The stated hospitalization cost of $8530 (2009$) is not representative of respiratory syncytial virus (RSV) hospitalizations among palivizumab-eligible infants; it is the average cost of bronchiolitis hospitalizations among US children ,2 years.2 Using the same source, the Kids’ Inpatient Database, the average RSV hospitalization (International Classification of Diseases, Ninth Revision, Clinic...
متن کاملEconomic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.
OBJECTIVE To systematically review all published economic analyses of the only 2 available agents for respiratory syncytial virus immunoprophylaxis in high-risk infants: respiratory syncytial virus immunoglobulin intravenous and palivizumab. DATA SOURCES Economic evaluations of respiratory syncytial virus immunoprophylactic agents were identified from the MEDLINE and HealthSTAR databases usin...
متن کاملStatistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
1 raised an important question of whether respiratory syncytial virus (RSV) hospitalizations increased following decreased use of RSV immunoprophylaxis among high-risk infants and children. The authors appropriately state that their analysis of 34,000 children <24 months of age provided 80% power to detect an increase from 5 to 7.5 RSV hospitalizations per 1000 children. However, the authors di...
متن کاملSix-month to 3-year follow-up of children with acute respiratory infections caused by respiratory syncytial virus
Background and Objective: This study was performed to investigate long-term complications of Respiratory Syncytial Viral infections in patients admitted to Ali Asghar Hospital with acute respiratory infections who presented to follow-up outpatient clinics 6 months to 3 years after discharge, between years 2009 and 2011. Methods: In this retrospective observational study that was performed in a...
متن کاملThe Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Most physicians (≥93.5%) routinely recommended immunoprophylaxis to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Pediatrics
دوره 133 4 شماره
صفحات -
تاریخ انتشار 2014